Health Care [ 11/12 ] | Biotechnology [ 48/74 ]
NASDAQ | Common Stock
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform.
It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis.
The company was founded in 2014 and is based in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | 0.12 Increased by +131.58% | -0.26 Increased by +146.15% |
| May 30, 24 | -0.19 Increased by +5.00% | -0.30 Increased by +36.67% |
| Feb 13, 24 | -0.30 Increased by +38.78% | -0.32 Increased by +6.25% |
| Nov 13, 23 | -0.40 Increased by +4.76% | -0.31 Decreased by -29.03% |
| Aug 14, 23 | -0.38 Increased by +20.83% | -0.30 Decreased by -26.67% |
| Jun 28, 23 | -0.20 Increased by +25.93% | -0.36 Increased by +44.44% |
| Feb 13, 23 | -0.49 Decreased by -19.51% | -0.39 Decreased by -25.64% |
| Nov 14, 22 | -0.42 Decreased by -31.25% | -0.42 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 55.13 M Increased by +154.96% | 95.30 M Increased by +132.66% | Increased by +172.85% Increased by +112.81% |
| Mar 31, 24 | 28.93 M Increased by +5.68% | -151.12 M Increased by +13.86% | Decreased by -522.35% Increased by +18.48% |
| Dec 31, 23 | 37.14 M Increased by +117.80% | 5.10 B Increased by +1.42 K% | Increased by +13.72 K% Increased by +707.90% |
| Sep 30, 23 | 37.10 M Increased by +196.03% | -304.33 M Increased by +3.67% | Decreased by -820.27% Increased by +67.46% |
| Jun 30, 23 | 21.62 M Increased by +400.67% | -291.82 M Increased by +17.52% | Decreased by -1.35 K% Increased by +83.53% |
| Mar 31, 23 | 27.38 M Increased by +196.82% | -175.42 M Increased by +39.78% | Decreased by -640.79% Increased by +79.71% |
| Dec 31, 22 | 17.05 M Decreased by -29.95% | -384.90 M Decreased by -35.27% | Decreased by -2.26 K% Decreased by -93.09% |
| Sep 30, 22 | 12.53 M Decreased by -10.40% | -315.92 M Decreased by -51.53% | Decreased by -2.52 K% Decreased by -69.11% |